351 related articles for article (PubMed ID: 35925319)
1. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
[TBL] [Abstract][Full Text] [Related]
2. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
5. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
Wong CKH; Lau KTK; Tang EHM; Lee CH; Lee CYY; Woo YC; Au ICH; Tan KCB; Lui DTW
Cardiovasc Diabetol; 2022 Jun; 21(1):92. PubMed ID: 35658864
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
8. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
9. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
12. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
[TBL] [Abstract][Full Text] [Related]
15. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
18. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
Zhou Y; Wang FR; Wen FF; Li C; Ye TT
Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
20. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
Qiu M; Ding L; Zhou H
Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]